ArticleScientific reports2025
Immune cells mediate the association between the plasma lipidome and pancreatic cancer: a Mendelian randomization analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An update on schistosomicide and tumoricide in the future: arachidonic acid.Lipids in health and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The plasma liposome was associated with pancreatic cancer (PC) but the specific mechanism was still unclear. We aim to investigate the relationship between the plasma lipidome and PC risk, as well as the mediating roles of immune cells. Based on summary genome-wide association study (GWAS) statistics of 179 plasma lipidomes, 791 immune cells, and PC patients of European ancestry, two-sample MR analysis was utilized to identify the relationship between the lipidome and PC. Then, the two-step MR method was used to investigate the mediating role of immune cells and calculate the mediation effects. Sensitivity analysis was employed to evaluate the reliability of the findings. According to the inverse variance weighted (IVW) results, higher phosphatidylcholine (O-16:0_20:4) (P = 0.0248), phosphatidylinositol (18:0_20:4) (P = 0.0268), triacylglycerol (54:6) (P = 0.0415), and sterol ester (27:1/15:0) (P = 0.0138) levels reduced PC risk, while phosphatidylcholine (16:0_20:3) (P = 0.0295) and higher sphingomyelin (d40:1) (P = 0.0217) levels increased PC risk. Additionally, 22 immune cells had an effect on PC. Among those, only CD4 Regulatory T (Treg) AC cells played a mediating role between phosphatidylinositol (18:0_20:4) and PC (proportion mediated: 10.5%). No significant heterogeneity or pleiotropy was observed. The present study showed that PC risk was impacted by phosphatidylcholine, phosphatidylinositol, triacylglycerol, sterol ester, and sphingomyelin levels. The causal relationship between phosphatidylinositol (18:0_20:4) and PC was mediated by CD4 Treg AC cells, which provides insight for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.